Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06802419
Recruiting Not applicable

Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries

NCT06802419 · tracked via the Priya Life Science Egypt tracker
Sponsor
Ain Shams University
Phase
Not applicable
Started
2025-01-30
Last updated
2025-01-31

Condition(s) studied

Continuous Adductor Canal BlockInfiltration Between The Popliteal Artery and Capsule of The KneeArthroscopic Knee Surgeries

Investigational drug(s) / intervention(s)

Continuous adductor canal blockContinuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule

Continuous adductor canal block: Patients will receive continuous adductor canal block.

Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule: Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee

Study summary

This study aims to evaluate the effect of Continuous Adductor Canal Block only versus adding posterior knee block, known as the Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) block with Continuous Adductor Canal Block (CACB) after arthroscopic knee surgeries.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 21 to 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) Physical Status Class I to II. * Patients with successful spinal anesthesia. * Patients scheduled for elective arthroscopic knee surgery for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) repair. Exclusion Criteria: * Declining to give written informed consent. * History of allergy to the medications used in the study. * Contraindications to regional anesthesia (including coagulopathy and local infection). * Polytrauma patients having lower limb fractures. * Patients with pre-existing myopathy or neuropathy on the operating limb. * Patients with diabetes mellitus. * Psychiatric disorder. * Morbid obesity \[body mass index (BMI) \> 45kg/m2\]. * Complicated Surgery.

Primary outcome measure(s)

  • Degree of pain — 24 hours postoperatively
    The degree of pain will be assessed using the Visual Analogue Scale (VAS). VAS score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. No pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt Recruiting

More Ain Shams University trials in Egypt

Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure Recruiting
3D Analysis of Soft Tissue Healing After Immediate Implant Placement Using PRF Vs HAM Active, not recruiting
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival Recruiting
Efficacy of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block for Postoperative Pain Control Following Video-assisted Thoracoscopic Surgeries (VATS): Randomized Control Trial Recruiting
Effect of Kangaroo Mother Care on Energy Utilization in Preterm Neonates Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06802419 on ClinicalTrials.gov ↗ ← All trials in Egypt